Impact of high-risk features on disease-free survival (DFS) in patients (pts) with high-risk stage II colon cancer (CC) in ACHIEVE-2 trial as part of the IDEA collaboration.

被引：0
|
作者：
Manaka, Dai
Shiozawa, Manabu
Kotaka, Masahito
Gamoh, Makio
Shiomi, Akio
Makiyama, Akitaka
Munemoto, Yoshinori
Rikiyama, Toshiki
Fukunaga, Mutsumi
Ueki, Takashi
Shitara, Kohei
Shinkai, Hiroshi
Tanida, Nobuyuki
Oki, Eiji
Yamazaki, Kentaro
Sunami, Eiji
Yamanaka, Takeharu
Yoshino, Takayuki
Ohtsu, Atsushi
Maehara, Yoshihiko
机构：
[1] Kyoto Katsura Hosp, Kyoto, Japan
[2] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Kanagawa, Japan
[3] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Hyogo, Japan
[4] Osaki Citizen Hosp, Dept Med Oncol, Osaki, Japan
[5] Shizuoka Canc Ctr Hosp, Div Colon & Rectal Surg, Shizuoka, Japan
[6] Japan Community Hlth Care Org, Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan
[7] Fukui Ken Saiseikai Hosp, Fukui, Japan
[8] Jichi Med Univ, Saitama, Japan
[9] Hyogo Prefectural Nishinomiya Hosp, Nishinomiya, Hyogo, Japan
[10] Hamanomachi Hosp, Dept Surg, Fukuoka, Japan
[11] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[12] Chigasaki Municipal Hosp, Dept Surg, Chigasaki, Kanagawa, Japan
[13] Japanese Red Cross Kochi Hosp, Dept Surg, Kochi, Japan
[14] Kyushu Univ, Fukuoka, Japan
[15] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[16] Japanese Red Cross Med Ctr, Dept Surg Oncol, Tokyo, Japan
[17] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan
[18] Kyushu Cent Hosp, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4011
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2-Early Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
  • [42] Association of NCCN guideline adherence with improved survival in high-risk stage II and stage III colon cancer.
    Boland, Genevieve Marie
    Chiang, Yj
    Chagpar, Ryaz
    Xing, Yan
    Hu, Chung-Yuan
    Feig, Barry W.
    Chang, George J.
    You, Y. Nancy
    Cormier, Janice N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [43] Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study
    Rosberg, Victoria
    Jessen, Mikkel
    Qvortrup, Camilla
    Smith, Henry George
    Krarup, Peter-Martin
    ACTA ONCOLOGICA, 2023, 62 (09) : 1076 - 1082
  • [44] The Prognostic Value of Micropapillary Pattern in Colon Cancer and Its Role as a High-Risk Feature in Patients With Stage II Disease
    Pyo, Dae Hee
    Kim, Seok-Hyung
    Shin, Jung Kyong
    Park, Yoonah
    Huh, Jung Wook
    Kim, Hee Cheol
    Yun, Seong Hyeon
    Lee, Woo Yong
    Cho, Yong Beom
    DISEASES OF THE COLON & RECTUM, 2023, 66 (11) : 1462 - 1472
  • [45] Adjuvant Chemotherapy Use and Outcomes of Patients With High-Risk Versus Low-Risk Stage II Colon Cancer
    Kumar, Aalok
    Kennecke, Hagen F.
    Renouf, Daniel J.
    Lim, Howard J.
    Gill, Sharlene
    Woods, Ryan
    Speers, Caroline
    Cheung, Winson Y.
    CANCER, 2015, 121 (04) : 527 - 534
  • [46] Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC)
    Ksienski, D.
    Gill, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer
    Du, Changzheng
    Xue, Weicheng
    Dou, Fangyuan
    Peng, Yifan
    Yao, Yunfeng
    Zhao, Jun
    Gu, Jin
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2017, 32 (03): : E267 - E273
  • [48] THE CHALLENGE TRIAL. A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENT WITH HIGH RISK STAGE II OR STAGE III COLON CANCER: A RANDOMISED CONTROLLED TRIAL
    Vardy, Janette
    Dhillon, Haryana M.
    van der Ploeg, Hidde
    Goddard, Emma
    Turner, Jane
    Kabourakis, Michael
    O'Brien, Patti
    Tu, DongSheng
    Booth, Chris
    O'Callaghan, Chris
    Courneya, Kerry
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 156 - 156
  • [49] Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).
    Yoshino, Takayuki
    Watanabe, Toshiaki
    Mori, Masaki
    Ohtsu, Atsushi
    Mizushima, Tsunekazu
    Yamazaki, Kentaro
    Sunami, Eiji
    Shirao, Kunlaki
    Sato, Atsushi
    Morita, Satoshi
    Yamanaka, Takeharu
    Gzothey, Axel
    Sargent, Daniel J.
    Sakamoto, Junichi
    Saji, Shigetoyo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] High-risk clinical and pathologic features define prognostic subsets among stage III colon cancer patients
    Rosales Sotomayor, A.
    Rosas, V.
    Noguez Ramos, A.
    Gamboa Dominguez, A.
    Huitzil Melendez, F. D.
    Mora-Pineda, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S349 - S349
12345